• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Pharma & Human Health

AI-Powered Precision Nutrition Plan by Enbiosis Improves IBS symptoms compared to low FODMAP diet

May 29, 2024 Microbiome Times

In a newly published study, Enbiosis’ AI-designed personalized diet was shown to significantly improve patients’ IBS symptoms. The results of this study provide further clinical evidence of Enbiosis’ expertise in AI-powered precision nutrition following their […]

Editor's Choice

The Clinical Journey of a Novel LBP for Bacterial Vaginosis Developed by MGH& Biose Industrie.

May 22, 2024 Microbiome Times

Current treatments for Bacterial Vaginosis, a condition caused by a disturbed vaginal microbiota resulting in certain bacteria becoming overgrown, comprise of antibiotics – tablets, gels, or creams. Antibiotics work by killing the overgrown bacteria to […]

Pharma & Human Health

Advancing Cardiovascular and Renal Health: The Collaboration between BioMe and Bacthera on BM109

April 10, 2024 Microbiome Times

BioMe, a prominent player in the field of Live Biotherapeutic Products (LBPs), has recently made significant strides with its latest drug development candidate, BM109, aimed at treating Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) […]

Pharma & Human Health

Bacteria subtype linked to growth in up to 50% of human colorectal cancers

March 26, 2024 Microbiome Times

Researchers at Fred Hutchinson Cancer Center have found that a specific subtype of a microbe commonly found in the mouth is able to travel to the gut and grow within colorectal cancer tumors. This microbe is also […]

Pharma & Human Health

Researchers Call for Regulation of Direct-to-Consumer Microbiome Tests

March 21, 2024 Microbiome Times

Scientific research has linked a person’s microbiome to everything from gut and mental health to immunity and predisposition to cancer. This research comes at a time when there is a burgeoning interest in wellness and […]

Finance

Dutch cabinet allocates €200 million for Holomicrobiome Institute

March 20, 2024 Microbiome Times

The government of the Netherlands has allocated €200 million from the country’s National Growth Fund for a public-private consortium that will conduct research into ‘microbiomes’ and economically interesting applications thereof. The funds, which will add […]

Finance

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

March 13, 2024 Microbiome Times

Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, with participation of all existing investors, reflects enthusiasm for […]

Finance

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50M Financing

March 7, 2024 Microbiome Times

BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a […]

Pharma & Human Health

New microbiome insights could help boost immunotherapy for a range of rare cancers

March 4, 2024 Microbiome Times

Researchers from the Wellcome Sanger Institute, the Olivia Newton-John Cancer Research Institute in Australia, and collaborators, have identified specific strains of bacteria that are linked with a positive response to combination immunotherapy in the largest […]

Finance

DNASense ApS Acquired by Clinical Microbiomics

March 4, 2024 Microbiome Times

Clinical Microbiomics announced the acquisition of DNASense ApS, an innovative Danish microbiome CRO specialized in long-read DNA and RNA sequencing technologies, and the associated cutting-edge bioinformatics. The acquisition expands Clinical Microbiomics’ expertise and offering for […]

Finance

Neobe Therapeutics Raises Over $2m For Synthetic Biology Enabled Tumour Microenvironment Remodelling

March 1, 2024 Microbiome Times

Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34M financing round. This significant financial milestone was achieved with the support of […]

Posts navigation

« 1 … 8 9 10 … 76 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter